Randomized Phase II Trial of Concomitant Chemoradiotherapy Using Weekly Carboplatin or Daily Low-Dose Cisplatin for Squamous Cell Carcinoma of the Head and Neck

Abstract

These findings suggest that weekly carboplatin treatment is preferable to daily low-dose cisplatin. This could be because the total dose of cisplatin was too low to be effective.

Cisplatin superior to carboplatin in adjuvant radiochemotherapy for locally advanced cancers of the oropharynx and oral cavity

“…In contrast to the phase III trial of De Andres et al [4], a randomized phase II study of 119 patients with stage II-IV SCCHN (53 stage II, 28 stage III, 38 stage IV) comparing weekly carboplatin (100 mg/m 2 ) to daily low-dose cisplatin (4 mg/m 2 ) for definitive concurrent radiochemotherapy suggested carboplatin to be the preferable agent [7]. The 5-year local control rates were 56% in the carboplatin group and 36% in the cisplatin group (p < 0.05), respectively, whereas the OS rates at 5 years were not significantly different (71% versus 66%).…”

“…The prognostic value of the performance status has been described by Lee et al [10] and Tribius et al [13]. The completion of the planned chemotherapy appeared to have played a certain role in the studies of Chitapanarux et al [3] and of Homma et al [7]. The prognostic impact of the interval between surgery and radiotherapy has been a matter of debate.…”

“…A randomized phase II study compared definitive radiochemotherapy with weekly carboplatin to definitive radiochemotherapy with low-dose cisplatin in patients with stage II-IV SCCHN [7]. Local control was significantly better in the carboplatin group.…”

Surgical complications of salvage total laryngectomy following concurrent chemoradiotherapy

“…11 Briefl y, CBDCA (100 mg/ m 2 ) was administered once a week, four times, while CDDP (4 mg/m 2 ) was administered daily for the fi rst 4 weeks. DOC (10 mg/m 2 ) was administered according to the protocol described by Fujii et al 13 Of the 34 group III patients, CBDCA was administered to 22, CDDP to 7, and DOC to 5.…”

“…At our institution, CCRT using low-dose chemotherapeutic agents, carboplatin (CBDCA), cisplatin (CDDP), and docetaxel (DOC) has been applied to patients with T2 and T3 laryngeal cancers. 3,11 Most patients with residual or recurrent disease after the completion of CCRT underwent total laryngectomy, though some were salvaged by larynxpreserving surgeries. In the present study, we analyzed the complications of salvage total laryngectomy after CCRT.…”